文献速递淋巴瘤造血干细胞移植与细胞治疗

自体干细胞移植前基于检查点抑制剂的挽救方案改善复发/难治性经典霍奇金淋巴瘤的无事件生存

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
PubMed 文献 · Am J Hematol · 2023-01-11

这项多中心回顾性队列纳入美国14家机构接受ASCT的936例R/R cHL患者,比较移植前传统化疗、BV+化疗、BV单药与CPI为基础方案的结局。校正至复发时间、移植前缓解和BV维持后,CPI组2年EFS为79.7%,优于传统化疗49.6%、BV+化疗62.3%和BV单药36.9%(p<.0001)。在仅接受1线挽救治疗后移植的649例中,CPI组2年PFS为98% vs 传统化疗68.8%(HR 0.1,95%CI 0.03-0.5,p<.0001)。

要点

  • CPI为基础方案移植前2年EFS 79.7%,传统化疗49.6%、BV+化疗62.3%、BV单药36.9%(p<.0001)。
  • 1线挽救后移植者CPI组2年PFS 98% vs 传统化疗68.8%(HR 0.1,95%CI 0.03-0.5,p<.0001)。
  • OS未因移植前挽救方案不同而存在差异。

核心结论

  • 在这项大型多中心回顾性研究中,CPI为基础方案较其他挽救方案改善EFS和PFS,且独立于移植前缓解。
  • 这些数据支持在R/R cHL移植前更早序贯使用CPI为基础方案。
  • OS未因移植前挽救方案不同而存在差异。

研究设计与样本

  • 多中心回顾性队列最终分析,纳入美国14家机构接受ASCT的R/R cHL患者。
  • 共936例,移植前接受传统化疗728例、BV+化疗73例、BV单药70例、CPI为基础方案65例。
  • 研究终点包括EFS、PFS和OS,所有终点均从复发时开始定义。

主要发现

  • 校正至复发时间、移植前缓解和BV维持后,CPI组2年EFS为79.7%,传统化疗为49.6%、BV+化疗为62.3%、BV单药为36.9%(p<.0001)。
  • 在1线挽救治疗后移植的649例中,CPI组2年PFS为98% vs 传统化疗68.8%(HR 0.1,95%CI 0.03-0.5,p<.0001)。
  • OS未因移植前挽救方案不同而存在差异。

关键数值与推荐

  • CPI为基础方案移植前2年EFS 79.7%,传统化疗49.6%、BV+化疗62.3%、BV单药36.9%(p<.0001)。
  • 1线挽救后移植者CPI组2年PFS 98% vs 传统化疗68.8%(HR 0.1,95%CI 0.03-0.5,p<.0001)。

临床怎么用

  • 数据支持在R/R cHL移植前更早序贯使用CPI为基础方案。
  • OS未因移植前挽救方案不同而存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant-eligible classic Hodgkin lymphoma (R/R cHL) but comparison with conventional chemotherapy is lacking. Herein, we report the final analysis of a multicenter retrospective cohort of R/R cHL assessing outcomes by type of salvage therapy before autologous stem cell transplant (ASCT). R/R cHL patients who underwent ASCT at 14 institutions across the United States were included. Outcomes were compared among patients receiving conventional chemotherapy, brentuximab vedotin (BV) + chemotherapy, BV alone, and a checkpoint inhibitor (CPI)-based regimens before ASCT. Study endpoints included event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). All endpoints are defined from relapse. Of 936 patients, 728 received conventional chemotherapy, 73 received BV + chemotherapy, 70 received BV alone, and 65 received CPI-based regimens prior to ASCT. When adjusted for time to relapse, pre-ASCT response and use of BV maintenance, patients receiving CPI-based regimens had superior 2-year EFS compared to conventional chemotherapy, BV + chemotherapy, and BV alone (79.7, 49.6, 62.3, and 36.9%, respectively, p < .0001). Among 649 patients transplanted after 1 line of salvage therapy, CPI-based regimens were associated with superior 2-year PFS compared to conventional chemotherapy (98% vs. 68.8%, hazard ratio: 0.1, 95% confidence interval: 0.03-0.5, p < .0001). OS did not differ by pre-ASCT salvage regimen. In this large multicenter retrospective study, CPI-based regimens improved EFS and PFS compared to other salvage regimens independent of pre-ASCT response. These data support earlier sequencing of CPI-based regimens in R/R cHL in the pre-ASCT setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023. PMID: 36629030. doi:10.1002/ajh.26827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。